Completed PHASE1 INTERVENTIONAL 3-arm NCT01485146

A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ETC-1002 at Doses Above 120 mg/Day in Healthy Subjects

Sponsor: Esperion Therapeutics, Inc.

Conditions Safety Evaluation of Escalating Doses

Interventions ETC-1002

Updated 8 times since 2017 Last updated: Mar 26, 2019 Started: Oct 25, 2011 Primary completion: Jan 25, 2012 Completion: Jan 25, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01485146, this PHASE1 trial focuses on Safety Evaluation of Escalating Doses and remains completed. Sponsored by Esperion Therapeutics, Inc., it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Feb 2021 [monthly]

Completed PHASE1
Apr 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Apr 2019 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Esperion Therapeutics, Inc.

Data source: Esperion Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kalamazoo, United States